Does vitamin D deficiency cause muscle weakness, myalgias, and fatigue?

Vitamin D deficiency is a highly prevalent clinical concern that has wide-ranging impacts on musculoskeletal health and general vitality. Adequate levels are critical for maintaining muscle integrity and systemic energy.

Clinical evidence of muscle weakness and fatigue

Evidence consistently links vitamin D deficiency (specifically serum 25(OH)D levels below 10–20 ng/mL) with proximal muscle weakness, diffuse myalgias, and systemic fatigue.

• Myalgia and weakness: Severe deficiency impairs muscle strength and increases fall risk, particularly in older and postmenopausal cohorts. Clinical trials show that targeted vitamin D replenishment in deficient individuals significantly reduces widespread musculoskeletal pain and restores proximal muscle function.
• Systemic fatigue: In a double-blind, randomized controlled trial of tired but otherwise healthy adults with low 25(OH)D, a single corrective dose of vitamin D3 led to statistically and clinically significant improvements in self-perceived fatigue compared to placebo.

Mechanistic pathways in skeletal muscle

Vitamin D functions as a direct regulator of skeletal muscle physiology via the genomic and non-genomic pathways of the vitamin D receptor (VDR).

• Excitation-contraction coupling: Non-genomic VDR activation triggers rapid intracellular calcium mobilization, directly modulating contractile quality and muscle power.
• Mitochondrial biogenesis: VDR signaling controls mitochondrial oxygen consumption, volume, and branching. It upregulates nuclear genes crucial for mitochondrial oxidative capacity, which supports myofiber energy demands and prevents catabolic degradation.
• Protein homeostasis: Active vitamin D signaling activates the anabolic Akt/mTOR axis and suppresses the local renin-angiotensin system, promoting protein synthesis and protecting against muscle atrophy.

Bottom line

• Vitamin D is a fundamental coordinator of skeletal muscle function. Deficiency is strongly associated with muscle weakness, myalgias, and fatigue, which can be clinically corrected by restoring 25(OH)D levels to support the receptor-mediated pathways that govern calcium handling, mitochondrial energy production, and muscle protein synthesis.